Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In their recent article in the Annals of the Rheumatic Diseases, van der Heijde D et al 1 evaluated the effect of certolizumab pegol (CZP) on radiographic progression in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis (nr-axSpA). They suggested that CZP-treated patients with axSpA had less modified Stokes Ankylosing Spondylitis Spinal Score (mSASSS) change and spinal progression at the end of 4 years. I read this fascinating article with interest. There is not an extra word to say about the design of the study, data presentation and valuable conclusion. But I noticed a conflict between table 1 (supplementary table 1) and supplementary table 2.
According to results of the study, there are 196 patients who had ≥1 mSASSS assessment, which is consistent with Supplementary table 2. But, according to table 1 and Supplementary table 1 of the study, there are 190 patients who have baseline mSASSS assessment, which is inconsistent with supplementary table 2. According to supplementary table 2, there is 193 patient who have baseline mSASSS assessment. I did not notice any explanation of this situation in the article. Although I am aware that three patients would not change the results of the study, I think this should be clarified.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; internally peer reviewed.